Аннотация:CAR-cell therapy is a promising new method of cancer treatment. The biomedical cell product Anti-HER2-CAR-T-NK cells has been found safe in a course of intraperitoneal injection at a human-equivalent therapeutic dose in male and female ICR mice. The obtained information can help in the future to form the basis of recommendations for preclinical studies of CAR-cell immunopreparations.